Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2024-02-15FDA Approved: VIVELLE-DOT — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for VIVELLE-DOT (estradiol) filed by Sandoz, resulting in labeling changes.
-
FDA label_change · 2014-12-02FDA Approved: ACTONEL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for ACTONEL (risendronate sodium) from Allergan, Inc., updating the product labeling.
-
FDA label_change · 2013-08-02FDA Approved: BINOSTO — Supplemental Application (Radius Health, Inc.)
The FDA approved a supplemental application for BINOSTO (alendronate sodium) from Radius Health, updating the product labeling.
-
FDA label_change · 2013-04-24FDA Approved: VIVELLE-DOT — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for VIVELLE-DOT (estradiol) from Sandoz Inc, resulting in updated labeling.
-
FDA label_change · 2011-01-25FDA Approved: ACTONEL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Actonel (risendronate sodium) filed by Allergan, Inc., to update the labeling related to its app…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2009-12-31FDA Approved: ACTONEL — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental NDA for Actonel (risendronate sodium) to update the labeling, potentially adding or revising indication…
-
FDA label_change · 2007-03-28FDA Approved: MENOSTAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA page indicates a supplemental application for Menostar (estradiol) by Bayer HealthCare Pharmaceuticals Inc., likely seeking changes to t…
-
FDA label_change · 2006-07-26FDA Approved: PREMARIN — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for PREMARIN (conjugated estrogens), resulting in changes to the product labeling.